Lord, Abbett & Co
NVAX icon

Lord, Abbett & Co’s Novavax NVAX Stock Holding History

Lord, Abbett & Co’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-312,926
Closed -$64.9M – 663
2021
Q3 		$64.9M Buy
+312,926
New +$69M 0.16% 208
2021
Q2 		– Sell
-50,061
Closed -$9.08M – 682
2021
Q1 		$9.08M Buy
+50,061
New +$9.98M 0.02% 542

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Lord, Abbett & Co's NVAX Position: Q4 2021 in Review

Lord, Abbett & Co sold out of Novavax (NVAX) in Q4 2021, closing a stake of 312,926 shares — an estimated $64.9M sold.

Lord, Abbett & Co first reported a position in NVAX in Q1 2021 and held it in 2 quarters. The position peaked at $64.9M in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

  • Lord, Abbett & Co reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 312,926 Novavax shares in Q4 2021, an estimated $64.9M.
  • Lord, Abbett & Co first reported a position in Novavax in Q1 2021 and held it in 2 quarters.
  • Lord, Abbett & Co's Novavax position peaked at $64.9M in Q3 2021.
  • 429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on Lord, Abbett & Co's 13F filing for Q4 2021, filed 11 Feb 2022.